Clinical Trials in Detroit

Showing 2641-2660 of 16,931 trials

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296

SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL with desirable potency and pharmaceutical properties. The study is being done to evaluate the safety and pharmacokinetic (PK) profile of SLC-391 in combination with pembrolizumab in participants with non-small cell lung cancer (NSCLC). Each treatment cycle lasts 21 days. Participants will swallow SLC-391 pills two times every day. Participants will get pembrolizumab intravenously (IV) from the study site staff on the first day of every cycle. This study has 2 parts. The first part will determine the recommended dose of SLC-391 in combination with pembrolizumab. The second part wants to find out if the combination of SLC-391 and pembrolizumab can help stop NSCLC tumours from growing or spreading.

Lung Cancer, Nonsmall CellLung Cancer Stage IVLung Cancer Metastatic

SignalChem Lifesciences Corporation36 participantsStarted May 2023

Indianapolis, Indiana, United States • Lafayette, Indiana, United States • Detroit, Michigan, United States +9 more locations

RECRUITINGPhase 1< 1 mile

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

NCT06551142

The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of GSK5764227. The study will also see how the levels of GSK5764227 will change over time at different dose amounts when administered alone and in combination with other medicines like carboplatin, cisplatin, atezolizumab, pembrolizumab, durvalumab, bevacizumab, cetuximab.

Neoplasms

GlaxoSmithKline590 participantsStarted Sep 2024

Stanford, California, United States • Denver, Colorado, United States • New Haven, Connecticut, United States +50 more locations

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

Find Trials by Condition in Detroit

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression

Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX

SyncAV Post-Market Trial

An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)

A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1)

Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens

The Johns Hopkins Heartburn Center Registry

A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

Study of Aspirin in Patients With Vestibular Schwannoma

DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study

An Observational LTFU Study for Patients Previously Treated With Autologous ex Vivo Gene Therapy for ADA-SCID

Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)